Clinical analysis of 215 elderly patients with cervical cancer.
- Author:
Min CHENG
1
;
Ling-ying WU
;
Wen-hua ZHANG
;
Man-ni HUANG
;
Rong ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; pathology; radiotherapy; surgery; Adenocarcinoma, Clear Cell; drug therapy; pathology; radiotherapy; surgery; Aged; Antineoplastic Agents; therapeutic use; Carcinoma, Squamous Cell; drug therapy; pathology; radiotherapy; surgery; Cisplatin; therapeutic use; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Neoplasm Staging; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms; drug therapy; pathology; radiotherapy; surgery; Young Adult
- From: Chinese Journal of Oncology 2009;31(5):388-391
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical features, treatment outcomes and possible prognostic factors in elderly patients with cervical cancer.
METHODSClinical data of 215 elderly women (> or = 65-years-old) with cervical cancer were retrospectively analyzed. Most patients (89.3%) had advanced stage ( II b-IV) disease. Eight of the 215 patients (3.7%) underwent surgical treatment, and six of those received postoperative radiotherapy. 133 patients received radiotherapy alone, and 74 patients underwent concurrent chemotherapy and radiotherapy.
RESULTSThe median follow-up time was 48 months (range: 12-102 months). The overall 5-year survival rate was 63.7%. The 5-year survival rate for stage I, II, III, IV were 83.2%, 76.4%, 39.0% and 0, respectively. There was no significant difference in 5-year survival rate between patients treated with concurrent chemotherapy combined with radiotherapy and radiotherapy alone. In multivariate analysis, lymph node metastasis, advanced stage, non-squamous histologies and poor differentiation were all negative prognostic factors for the overall survival.
CONCLUSIONThe treatment strategy for elderly cervical cancer patients should be individually planned according to the disease stage and performance status of the patients. Usually, one radical therapy modality can be chosen, and combined modality therapy is not suggested.
